Shares in Chugai Pharmaceutical, Japan's largest drugmaker, have tumbled the most since 1977 after late-stage trial data on an obesity drug it licensed to Eli Lilly & Co. showed disappointing results. https://www.japantimes.co.jp/business/2025/08/08/companies/chugai-shares-sink/?utm_medium=Social&utm_source=mastodon #business #companies #chugai #health #pharmaceuticals #obesity
A health ministry panel approved a plan to cut the price of Lecanemab, an Alzheimer's drug that Japanese drugmaker Eisai and U.S. industry peer Biogen codeveloped, by 15% in Japan starting Nov. 1. https://www.japantimes.co.jp/news/2025/08/07/japan/science-health/japan-alzheimer-drug-price-cut/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #alzheimer039s #medicine #pharmaceuticals#eisai #health
A Kyoto University research team has developed a pain-reliever that is comparable to morphine but does not have serious side effects. https://www.japantimes.co.jp/news/2025/08/05/japan/japan-new-painkiller-comparable-to-morphine/?utm_medium=Social&utm_source=mastodon #japan #health #medicine #pharmaceuticals #cancer #kyotouniversity
Japan's Kobayashi Pharmaceutical will accelerate efforts to reform its corporate culture marked by workers' reliance on top management, Chairman Yoshihito Ota has said. https://www.japantimes.co.jp/business/2025/08/04/companies/kobayashi-pharmaceutical-corporate-culture-reform/?utm_medium=Social&utm_source=mastodon #business #companies #kobayashipharmaceutical #osaka #pharmaceuticals #health #corporategovernance
The FDA is cracking down on a generic drugmaker that was the subject of a ProPublica investigation last year, citing problems with safety tests that delayed the recall of a faulty medicine linked to deaths in the U.S.
https://www.propublica.org/article/fda-letter-glenmark-pharmaceuticals?utm_source=mastodon&utm_medium=social&utm_campaign=mastodon-post
The biotechnology industry is experiencing a tectonic shift, driven by Chinese drugmakers who have come a long way from their copycat days to challenge Western dominance on innovation. https://www.japantimes.co.jp/business/2025/07/14/tech/china-biotech-world-drug-pipeline/?utm_medium=Social&utm_source=mastodon #business #tech #biotech #pharmaceuticals #china #medicine
U.S. President Donald Trump has vowed to push forward with his aggressive tariff regime, stressing he would not offer additional extensions on country-specific levies set to now hit in early August. https://www.japantimes.co.jp/business/2025/07/09/markets/trump-tariff-copper-drugs/?utm_medium=Social&utm_source=mastodon #business #markets #us #donaldtrump #trade #tariffs #republicans #copper #pharmaceuticals
Kobayashi Pharmaceutical remains only halfway through overhauling its corporate governance, as it struggles to restore public trust after health problems linked to some of its dietary supplements more than a year ago. https://www.japantimes.co.jp/business/2025/07/08/companies/kobayashi-reform-founding-family/?utm_medium=Social&utm_source=mastodon #business #companies #kobayashipharmaceutical #pharmaceuticals #corporategovernance #koji #health #norikazutoyoda
Drug wholesaler Medipal Holdings is seeking merger and acquisition opportunities to diversify its business and combat slower growth in the market in Japan. https://www.japantimes.co.jp/business/2025/07/01/companies/japan-medipal-drug-firm-ma/?utm_medium=Social&utm_source=mastodon #business #companies #medipalholdings #pharmaceuticals #acquisitions #mergers